Therapy  ||| S:0 E:8 ||| JJ
refractory  ||| S:8 E:19 ||| JJ
menorrhagia  ||| S:19 E:31 ||| NN
as  ||| S:31 E:34 ||| IN
first  ||| S:34 E:40 ||| JJ
manifestation  ||| S:40 E:54 ||| NN
of  ||| S:54 E:57 ||| IN
Hermansky-Pudlak  ||| S:57 E:74 ||| JJ
syndrome  ||| S:74 E:83 ||| NN
Oculocutaneous  ||| S:83 E:98 ||| FW
albinism  ||| S:98 E:107 ||| FW
( ||| S:107 E:108 ||| -LRB-
OCA ||| S:108 E:111 ||| NNP
)  ||| S:111 E:113 ||| -RRB-
in  ||| S:113 E:116 ||| IN
combination  ||| S:116 E:128 ||| NN
with  ||| S:128 E:133 ||| IN
a  ||| S:133 E:135 ||| DT
platelet  ||| S:135 E:144 ||| JJ
function  ||| S:144 E:153 ||| NN
defect  ||| S:153 E:160 ||| VBZ
caused  ||| S:160 E:167 ||| VBN
by  ||| S:167 E:170 ||| IN
a  ||| S:170 E:172 ||| DT
disturbed  ||| S:172 E:182 ||| JJ
release  ||| S:182 E:190 ||| NN
reaction  ||| S:190 E:199 ||| NN
from  ||| S:199 E:204 ||| IN
platelet  ||| S:204 E:213 ||| JJ
δ-granules  ||| S:213 E:224 ||| NN
( ||| S:224 E:225 ||| -LRB-
storage  ||| S:225 E:233 ||| NN
pool  ||| S:233 E:238 ||| NN
defect  ||| S:238 E:245 ||| NN
-  ||| S:245 E:247 ||| :
SPD ||| S:247 E:250 ||| NNP
)  ||| S:250 E:252 ||| -RRB-
is  ||| S:252 E:255 ||| VBZ
typical  ||| S:255 E:263 ||| JJ
for  ||| S:263 E:267 ||| IN
the  ||| S:267 E:271 ||| DT
autosomal  ||| S:271 E:281 ||| JJ
recessive  ||| S:281 E:291 ||| NN
inherited  ||| S:291 E:301 ||| VBD
Hermansky-Pudlak  ||| S:301 E:318 ||| JJ
syndrome  ||| S:318 E:327 ||| NN
( ||| S:327 E:328 ||| -LRB-
HPS ||| S:328 E:331 ||| NNP
) ||| S:331 E:332 ||| -RRB-
.  ||| S:332 E:334 ||| .
A  ||| S:334 E:336 ||| DT
girl  ||| S:336 E:341 ||| NN
( ||| S:341 E:342 ||| -LRB-
age ||| S:342 E:345 ||| NN
:  ||| S:345 E:347 ||| :
13  ||| S:347 E:350 ||| CD
years ||| S:350 E:355 ||| NNS
)  ||| S:355 E:357 ||| -RRB-
with  ||| S:357 E:362 ||| IN
OCA  ||| S:362 E:366 ||| NNP
was  ||| S:366 E:370 ||| VBD
hospitalized  ||| S:370 E:383 ||| VBN
with  ||| S:383 E:388 ||| IN
transfusion-requiring  ||| S:388 E:410 ||| JJ
menorrhagia ||| S:410 E:421 ||| NN
.  ||| S:421 E:423 ||| .
The  ||| S:423 E:427 ||| DT
suspicion  ||| S:427 E:437 ||| NN
of  ||| S:437 E:440 ||| IN
HPS  ||| S:440 E:444 ||| NNP
was  ||| S:444 E:448 ||| VBD
confirmed  ||| S:448 E:458 ||| VBN
by  ||| S:458 E:461 ||| IN
results  ||| S:461 E:469 ||| NNS
of  ||| S:469 E:472 ||| IN
lumi-aggregometry ||| S:472 E:489 ||| JJ
.  ||| S:489 E:491 ||| .
Suspecting  ||| S:491 E:502 ||| VBG
a  ||| S:502 E:504 ||| DT
disorder  ||| S:504 E:513 ||| NN
in  ||| S:513 E:516 ||| IN
primary  ||| S:516 E:524 ||| JJ
haemostasis  ||| S:524 E:536 ||| JJ
treatment  ||| S:536 E:546 ||| NN
with  ||| S:546 E:551 ||| IN
tranexamic  ||| S:551 E:562 ||| JJ
acid  ||| S:562 E:567 ||| NN
( ||| S:567 E:568 ||| -LRB-
10  ||| S:568 E:571 ||| CD
mg ||| S:571 E:573 ||| CD
/ ||| S:573 E:574 ||| CD
kg  ||| S:574 E:577 ||| JJ
body  ||| S:577 E:582 ||| NN
weight  ||| S:582 E:589 ||| NN
every  ||| S:589 E:595 ||| DT
8  ||| S:595 E:597 ||| CD
h  ||| S:597 E:599 ||| CD
i.  ||| S:599 E:602 ||| CD
v. ||| S:602 E:604 ||| CD
) ||| S:604 E:605 ||| -RRB-
,  ||| S:605 E:607 ||| ,
desmopressin  ||| S:607 E:620 ||| NNS
( ||| S:620 E:621 ||| -LRB-
0.3  ||| S:621 E:625 ||| CD
µg ||| S:625 E:627 ||| CD
/ ||| S:627 E:628 ||| CD
kg  ||| S:628 E:631 ||| JJ
body  ||| S:631 E:636 ||| NN
weight  ||| S:636 E:643 ||| NN
every  ||| S:643 E:649 ||| DT
8  ||| S:649 E:651 ||| CD
to  ||| S:651 E:654 ||| TO
12  ||| S:654 E:657 ||| CD
h ||| S:657 E:658 ||| CD
)  ||| S:658 E:660 ||| -RRB-
and  ||| S:660 E:664 ||| CC
hormonal  ||| S:664 E:673 ||| JJ
therapy  ||| S:673 E:681 ||| NN
( ||| S:681 E:682 ||| -LRB-
norethisterone ||| S:682 E:696 ||| LS
)  ||| S:696 E:698 ||| -RRB-
was  ||| S:698 E:702 ||| VBD
started  ||| S:702 E:710 ||| VBN
but  ||| S:710 E:714 ||| CC
the  ||| S:714 E:718 ||| DT
menorrhagia  ||| S:718 E:730 ||| JJ
persisted ||| S:730 E:739 ||| NN
.  ||| S:739 E:741 ||| .
Clinical  ||| S:741 E:750 ||| JJ
response  ||| S:750 E:759 ||| NN
was  ||| S:759 E:763 ||| VBD
finally  ||| S:763 E:771 ||| RB
achieved  ||| S:771 E:780 ||| VBN
by  ||| S:780 E:783 ||| IN
a  ||| S:783 E:785 ||| DT
single  ||| S:785 E:792 ||| JJ
injection  ||| S:792 E:802 ||| NN
of  ||| S:802 E:805 ||| IN
100  ||| S:805 E:809 ||| CD
µg ||| S:809 E:811 ||| FW
/ ||| S:811 E:812 ||| FW
kg  ||| S:812 E:815 ||| FW
body  ||| S:815 E:820 ||| FW
weight  ||| S:820 E:827 ||| FW
recombinant  ||| S:827 E:839 ||| FW
factor  ||| S:839 E:846 ||| FW
VIIa  ||| S:846 E:851 ||| FW
( ||| S:851 E:852 ||| -LRB-
rFVIIa ||| S:852 E:858 ||| NNP
) ||| S:858 E:859 ||| -RRB-
.  ||| S:859 E:861 ||| .
The  ||| S:861 E:865 ||| DT
diagnosis  ||| S:865 E:875 ||| NN
of  ||| S:875 E:878 ||| IN
HPS  ||| S:878 E:882 ||| NNP
should  ||| S:882 E:889 ||| MD
be  ||| S:889 E:892 ||| VB
suspected  ||| S:892 E:902 ||| VBN
in  ||| S:902 E:905 ||| IN
patients  ||| S:905 E:914 ||| NNS
with  ||| S:914 E:919 ||| IN
OCA  ||| S:919 E:923 ||| NNP
and  ||| S:923 E:927 ||| CC
bleeding  ||| S:927 E:936 ||| VBG
symptoms  ||| S:936 E:945 ||| NNS
and  ||| S:945 E:949 ||| CC
is  ||| S:949 E:952 ||| VBZ
confirmed  ||| S:952 E:962 ||| VBN
by  ||| S:962 E:965 ||| IN
the  ||| S:965 E:969 ||| DT
proof  ||| S:969 E:975 ||| NN
of  ||| S:975 E:978 ||| IN
SPD ||| S:978 E:981 ||| NNP
.  ||| S:981 E:983 ||| .
In  ||| S:983 E:986 ||| IN
case  ||| S:986 E:991 ||| NN
of  ||| S:991 E:994 ||| IN
absent  ||| S:994 E:1001 ||| JJ
clinical  ||| S:1001 E:1010 ||| JJ
response  ||| S:1010 E:1019 ||| NN
to  ||| S:1019 E:1022 ||| TO
desmopressin  ||| S:1022 E:1035 ||| VB
the  ||| S:1035 E:1039 ||| DT
application  ||| S:1039 E:1051 ||| NN
of  ||| S:1051 E:1054 ||| IN
rFVIIa  ||| S:1054 E:1061 ||| NNP
should  ||| S:1061 E:1068 ||| MD
be  ||| S:1068 E:1071 ||| VB
considered ||| S:1071 E:1081 ||| VBN
.  ||| S:1081 E:1083 ||| .
Hormones  ||| S:1083 E:1092 ||| NNP
and  ||| S:1092 E:1096 ||| CC
antifibrinolytics  ||| S:1096 E:1114 ||| NNS
are  ||| S:1114 E:1118 ||| VBP
useful  ||| S:1118 E:1125 ||| JJ
options  ||| S:1125 E:1133 ||| NNS
in  ||| S:1133 E:1136 ||| IN
the  ||| S:1136 E:1140 ||| DT
treatment  ||| S:1140 E:1150 ||| NN
of  ||| S:1150 E:1153 ||| IN
extensive  ||| S:1153 E:1163 ||| JJ
menorrhagia ||| S:1163 E:1174 ||| NN
.  ||| S:1174 E:1176 ||| .
